IDXX

IDEXX Laboratories, Inc. - Q1 2006 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2006. IDEXX Laboratories, Inc. operates primarily through three segments: Companion Animal Group (CAG), Water testing, and Food Diagnostics Group (FDG). The company is a large accelerated filer incorporated in Delaware. As of April 28, 2006, 31,556,297 shares of common stock were outstanding.

Key Financial Metrics

Note: Working capital calculated as Total Current Assets minus Total Current Liabilities.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 10.3% year-over-year. Organic growth (net of currency effects) was 13.0%.
  • CAG: Revenue rose 11.6% (13.9% organic), driven by growth in laboratory services (19.3%) and digital radiography (29.9%).
  • FDG: Revenue rose 13.5% (20.3% organic), led by production animal products.
  • Water: Revenue declined 5.8% (3.3% organic) due to lower sales volume.
• Accounting Change (SFAS 123(R)): Effective January 1, 2006, the company adopted SFAS No. 123(R) for share-based compensation. This resulted in a $2.8 million expense recognition ($2.4 million in operating expenses), which reduced operating income margin by approximately 2% compared to the prior year where no such expense was recognized.
• Cash Flow: Net cash used by operating activities was $3.0 million, compared to $0.3 million provided in Q1 2005. This shift was primarily due to a $9.6 million increase in inventory (specifically VetTest slides) and a reclassification of $4.7 million in tax benefits from stock option exercises from operating to financing activities.
• Share Repurchases: The company repurchased 541,000 shares for $42.7 million during the quarter.

Guidance, Outlook, and Risks

• Pharmaceutical Outlook: Management expects pharmaceutical revenue for the full year 2006 to grow at a lower rate of 15% to 20% compared to 2005.
• Water Segment: Management expects the full-year 2006 growth rate for the Water segment to be in the mid-single digits.
• Tax Rate: The effective tax rate is expected to be approximately 33% to 34% for the full year 2006.
• Capital Budget: The total capital budget for 2006 for fixed assets and rental instruments is approximately $40.0 million.
• Risks and Contingencies:
  • FDA Regulatory Issues: The FDA deemed the company's new animal drug application (NADA) for a long-acting feline antibiotic incomplete. The company is conducting studies to address these issues. Failure to launch could result in an impairment charge on $13.7 million of goodwill associated with the pharmaceutical unit.
  • Supply Chain: The company relies on limited sources for key components (e.g., VetTest slides, VetAutoread analyzers). Minimum purchase obligations exist under supplier agreements.
  • Real Estate: The company agreed to purchase its headquarters for $17.9 million (assuming a $6.5 million mortgage), expected to close in May 2006.

Investor Verification Checklist

• Inventory Build-up: Verify the rationale and timing for the $11.7 million increase in inventory, specifically regarding the deferral of VetTest slide receipts.
• Pharmaceutical Pipeline: Monitor the status of the FDA studies for the feline antibiotic and the potential risk of goodwill impairment ($13.7 million).
• Share-Based Compensation Impact: Assess the long-term impact of SFAS 123(R) adoption on future operating margins and tax rates.
• Distributor Inventory: Review distributor purchasing dynamics, as fluctuations in distributor inventory levels can distort reported revenue growth relative to end-user demand.
• Currency Exposure: Evaluate the impact of foreign currency fluctuations, which negatively affected reported revenue growth by approximately 2.7% in the quarter.